Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.

by Gregory Y H Lip, Xianying Pan, Shital Kamble, Hugh Kawabata, Jack Mardekian, Cristina Masseria, Hemant Phatak
Published 2018-01-01

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.

by Ping G Tepper, Jack Mardekian, Cristina Masseria, Hemant Phatak, Shital Kamble, Younos Abdulsattar, William Petkun, Gregory Y H Lip
Published 2018-01-01